Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRVA Stock Forecast 2025-2026
$23.80
Current Price
$2.99B
Market Cap
Buy 19
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to PRVA Price Targets
+51.3%
To High Target of $36.00
+26.1%
To Median Target of $30.00
-3.4%
To Low Target of $23.00
PRVA Price Momentum
-4.4%
1 Week Change
+4.1%
1 Month Change
+44.8%
1 Year Change
+21.7%
Year-to-Date Change
-8.8%
From 52W High of $26.09
+49.5%
From 52W Low of $15.92
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Privia Health (PRVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRVA and similar high-potential opportunities.
Latest PRVA Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, PRVA has a bullish consensus with a median price target of $30.00 (ranging from $23.00 to $36.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $23.80, the median forecast implies a 26.1% upside. This outlook is supported by 19 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Dodge at RBC Capital, projecting a 51.3% upside. Conversely, the most conservative target is provided by Andrew Mok at Barclays, suggesting a 3.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRVA Analyst Ratings
19
Buy
2
Hold
0
Sell
PRVA Price Target Range
Low
$23.00
Average
$30.00
High
$36.00
Current: $23.80
Latest PRVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 28, 2025 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $29.00 |
| Apr 15, 2025 | Baird | Michael Ha | Outperform | Maintains | $26.00 |
| Apr 10, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $23.00 |
| Apr 10, 2025 | Needham | Matthew Sheerin | Buy | Reiterates | $30.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $28.00 |
| Mar 21, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $30.00 |
| Feb 28, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $30.00 |
| Feb 28, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $30.00 |
| Feb 28, 2025 | Piper Sandler | Sean Wieland | Overweight | Maintains | $40.00 |
| Feb 28, 2025 | Citizens Capital Markets | Constantine Davides | Market Outperform | Maintains | $29.00 |
| Feb 14, 2025 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $26.00 |
| Jan 15, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $25.00 |
| Jan 10, 2025 | Needham | Matthew Sheerin | Buy | Initiates | $25.00 |
| Jan 7, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
| Jan 2, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
| Dec 16, 2024 | Macquarie | Outperform | Initiates | $0.00 | |
| Nov 29, 2024 | JP Morgan | Lisa Gill | Overweight | Maintains | $28.00 |
| Nov 8, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $27.00 |
| Nov 8, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $21.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Overweight | Initiates | $23.00 |
Privia Health Group Inc. (PRVA) Competitors
The following stocks are similar to Privia Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PRVA
Privia Health
mkt cap
3.05B
Privia Health Group Inc. (PRVA) Financial Data
Privia Health Group Inc. has a market capitalization of $2.99B with a P/E ratio of 204.3x. The company generates $1.80B in trailing twelve-month revenue with a 0.9% profit margin.
Revenue growth is +15.6% quarter-over-quarter, while maintaining an operating margin of +1.1% and return on equity of +3.0%.
Valuation Metrics
Market Cap
$2.99B
Enterprise Value
$2.58B
P/E Ratio
204.3x
PEG Ratio
94.3x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+15.6%
Gross Margin
+9.5%
Operating Margin
+1.1%
Net Margin
+0.9%
EPS Growth
+41.4%
Financial Health
Cash/Price Ratio
+16.2%
Current Ratio
1.9x
Debt/Equity
0.8x
ROE
+3.0%
ROA
+1.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Privia Health Group Inc. (PRVA) Business Model
About Privia Health Group Inc.
What They Do
Enhances healthcare delivery through technology integration.
Business Model
The company partners with medical groups and health plans to create a network that optimizes patient outcomes and improves provider workflows using data analytics. It generates revenue by offering a cloud-based platform that facilitates communication and coordination among healthcare professionals and patients, focusing on value-based care models.
Additional Information
Privia Health plays a crucial role in the transition from fee-for-service to value-based healthcare, emphasizing cost efficiency and patient-centered care. Its operations reflect the growing trend of digital transformation within the healthcare services sector.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,140
CEO
Mr. Parth Mehrotra
Country
United States
IPO Year
2021
Website
www.priviahealth.comPrivia Health Group Inc. (PRVA) Latest News & Analysis
Latest News
Quick Summary
Privia Health Group, Inc. (NASDAQ:PRVA) will hold its Q1 2025 Earnings Conference Call on May 8, 2025, at 8:00 AM ET, featuring key executives and various financial analysts.
Why It Matters
The earnings call for Privia Health Group provides insights into financial performance, guidance, and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Privia Health Group reported strong Q1 results for 2025 and raised its full-year outlook to the mid- to high end of guidance, with attributed lives remaining unchanged.
Why It Matters
Privia Health's strong Q1 performance and raised guidance indicate robust growth potential, signaling positive momentum that could enhance investor confidence and drive stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Privia Health (PRVA) reported quarterly earnings of $0.03 per share, below the Zacks Consensus Estimate of $0.06, and up from $0.02 per share a year earlier.
Why It Matters
Privia Health's earnings miss signals potential operational challenges, which may lead to decreased investor confidence and impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Privia Health's Q1 2025 financial results show top- and bottom-line performance. Key metrics should be compared to Wall Street estimates and year-ago figures for a comprehensive evaluation.
Why It Matters
Comparing Privia Health's performance metrics to estimates and previous results helps assess growth potential and market position, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Countdown to Privia Health (PRVA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
15 days ago
Quick Summary
Privia Health (PRVA) is set to report its Q1 2025 performance, with investors encouraged to analyze key metrics beyond standard revenue and earnings estimates.
Why It Matters
The focus on key metrics beyond traditional estimates can reveal Privia Health's underlying performance, influencing investment decisions and expectations for future growth.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
2 months ago
Quick Summary
Experts suggest that investors consider stocks with strong earnings growth potential instead of focusing solely on mega-cap stocks like Meta, Amazon, and Netflix amid market volatility.
Why It Matters
Shifting focus from mega-cap stocks to those with strong earnings growth suggests potential for higher returns amid market volatility, indicating a strategic change in investment opportunities.
Source: Invezz
Market Sentiment:
Positive
Frequently Asked Questions About PRVA Stock
What is Privia Health Group Inc.'s (PRVA) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Privia Health Group Inc. (PRVA) has a median price target of $30.00. The highest price target is $36.00 and the lowest is $23.00.
Is PRVA stock a good investment in 2025?
According to current analyst ratings, PRVA has 19 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRVA stock?
Wall Street analysts predict PRVA stock could reach $30.00 in the next 12 months. This represents a 26.1% increase from the current price of $23.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Privia Health Group Inc.'s business model?
The company partners with medical groups and health plans to create a network that optimizes patient outcomes and improves provider workflows using data analytics. It generates revenue by offering a cloud-based platform that facilitates communication and coordination among healthcare professionals and patients, focusing on value-based care models.
What is the highest forecasted price for PRVA Privia Health Group Inc.?
The highest price target for PRVA is $36.00 from Sean Dodge at RBC Capital, which represents a 51.3% increase from the current price of $23.80.
What is the lowest forecasted price for PRVA Privia Health Group Inc.?
The lowest price target for PRVA is $23.00 from Andrew Mok at Barclays, which represents a -3.4% decrease from the current price of $23.80.
What is the overall PRVA consensus from analysts for Privia Health Group Inc.?
The overall analyst consensus for PRVA is bullish. Out of 25 Wall Street analysts, 19 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PRVA stock price projections?
Stock price projections, including those for Privia Health Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 8:08 PM UTC